← CG Oncology, Inc. (CGON) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CG Oncology, Inc. (CGON)
Biological Products, (No Diagnostic Substances) · market cap $6.6B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
3
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
CG Oncology (CGON) is a small-cap oncology biotech focused on bladder cancer, with lead asset cretostimogene grenadenorepvec in Phase 3 for high-risk non-muscle-invasive bladder cancer (NMIBC). The company posted a positive Phase 3 readout on 2026-06-15 and is tracking toward an estimated PDUFA date of 2027-06-05, but carries a critically thin cash runway of ~1.8 months and elevated dilution risk.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
- 2027-03-31 (est.)Phase 2 · Cretostimogene Grenadenorepvecimp 7/10
- 2027-03-31 (est.)Phase 3 · Cretostimogene Grenadenorepvecimp 9/10
- 2027-06-05 (est.)PDUFAimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CG0070 | Phase 2 | Non Muscle Invasive Bladder Cancer |
| Cretostimogene Grenadenorepvec | Phase 3 | High-Risk Non-Muscle-Invasive Bladder Cancer |
| Ivaltinostat | Phase 2 | Metastatic Pancreatic Adenocarcinoma |
Price & technical context
3-month
-2.9%
6-month
+2.3%
12-month
+69.7%
52-wk range
$37.37–$80.68
vs 50-day MA
-7.7%
vs 200-day MA
+7.2%
Realized vol
54.7%
Max drawdown
-61.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CGON (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.